TrueBinding

What TrueBinding does

TrueBinding, Inc. is a clinical-stage biotherapeutics company founded in 2016 and headquartered in Santa Clara, California. The company develops a proprietary platform centered on neutralizing Galectin-3 (Gal-3), a pleiotropic protein identified as a master regulator of chronic inflammation, protein aggregation, fibrosis, and cellular senescence. The lead product, TB006, is a humanized monoclonal antibody designed to bind Gal-3 and inhibit its Low-Complexity Domain (LCD), which promotes liquid-liquid phase separation and pathogenic aggregation of amyloid-beta, tau, alpha-synuclein, and apolipoprotein E4. The mechanism underpins development across multiple indications including Alzheimer's disease, Parkinson's disease, Autism Spectrum Disorder, Acute Ischemic Stroke, COVID-19, and Glioblastoma.

TrueBinding's go-to-market is exclusively physician-mediated. Pre-commercial revenue is limited to cost recovery through an FDA-authorized Expanded Access Program (EAP) for eligible patients with dementia and Alzheimer's disease, with international access via a Hong Kong Department of Health Named Patient Program and a broader Global Early Access Program. Distribution is direct-to-physician with a network of approximately 20 US investigators; physicians must apply, complete training, and oversee monthly IV infusions of TB006. There are no direct-to-consumer sales, and TB006 is not commercially approved. Pricing is not publicly disclosed; patients pay FDA-approved manufacturing costs plus physician and monitoring fees.

The company has raised approximately $247 million across disclosed rounds between 2019 and 2023, including a $100M round in July 2022 and a $78.2M Form D offering filed in July 2023 with ChinaNetCenter as a known investor. Leadership includes founder George Hong, CEO Dongxu Sun, CMO Alan K. Jacobs (ex-Sanofi Genzyme, Immunovant, Boston Pharmaceuticals), COO Fan Chen (ex-AstraZeneca, MedImmune, Dendreon), and CDO Brian Z. Ring (ex-Stanford). Scientific advisory ties include NYU Langone, University of Kansas Medical Center, UCSF, and UCI. Clinical momentum includes positive Phase 1b/2a Alzheimer's topline data, completion of Phase 2a Parkinson's enrollment (April 2026), and ongoing Phase 2a Autism dosing, supported by continuous FDA EAP renewals through 2026.

Name

TrueBinding

Legal name

TrueBinding, Inc.

Website

https://truebinding.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

TrueBinding is a clinical-stage biotherapeutics company developing TB006, a humanized monoclonal antibody neutralizing Galectin-3 to treat Alzheimer's, Parkinson's, autism, and glioblastoma. It distributes TB006 pre-approval via FDA-authorized Expanded Access Programs to patients and specialty physicians.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Monoclonal Antibody Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)

Keywords

• Monoclonal antibody therapeutics
• Neurodegenerative disease treatment
• Biopharmaceutical drug development
• Expanded access programs
• Clinical stage biotherapeutics

Headquarters

HQ city

Santa Clara

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Expanded Access Program (EAP): TrueBinding currently recovers manufacturing costs through its FDA-authorized Expanded Access Program. Patients pay for the drug manufacturing costs, physician fees, and laboratory monitoring costs. The company is in clinical development stage with TB006 not yet commercially approved.
2. Future Drug Commercialization: Post-approval, the company expects to generate revenue through commercial sales of TB006 and potentially other pipeline products targeting Galectin-3 across multiple indications including Alzheimer's, Parkinson's, autism, glioblastoma, and other conditions.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

TrueBinding develops TB006, a humanized monoclonal antibody that targets Galectin-3 (Gal-3) to neutralize chronic inflammation, protein aggregation, and fibrosis implicated in neurodegenerative and age-related diseases. The product is administered as a monthly IV infusion and is currently provided to eligible patients under an FDA-authorized Expanded Access Program and international Named Patient Programs while clinical development continues across Alzheimer's, Parkinson's, Autism Spectrum Disorder, Glioblastoma, and acute ischemic stroke indications.

Product overview

TrueBinding is a clinical-stage biotherapeutics company pioneering a broad-spectrum healthspan platform targeting Galectin-3 (Gal-3). The company's core product is TB006, an investigational humanized monoclonal antibody designed to neutralize Gal-3 and halt toxic feedback loops of neuroinflammation, protein aggregation, and systemic tissue damage. TB006 is being developed across multiple therapeutic indications including Alzheimer's disease, Parkinson's disease, Autism Spectrum Disorder, and Glioblastoma. The company operates Expanded Access Programs (EAPs) in the USA and globally (including Hong Kong) to provide access to TB006 for eligible patients outside of clinical trials. The TrueBinding platform is built around targeting Gal-3 as the master regulator of chronic inflammation and age-related decline.

Differentiator

Problem solved

Functional benefit

Brands

• TB006: Investigational monoclonal antibody drug targeting Galectin-3 (Gal-3) for treatment of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions
• TrueBinding Platform
• Expanded Access Program (EAP)

Products and services

• TB006 TB006 is an investigational humanized monoclonal antibody that targets Galectin-3 (Gal-3), a pleiotropic protein involved in chronic inflammation, protein aggregation, fibrosis, and cellular senescence. It is designed to neutralize Gal-3 to resolve chronic inflammaging and is administered as a monthly IV infusion to patients with serious neurodegenerative and age-related conditions including Alzheimer's disease, Parkinson's disease, Autism Spectrum Disorder, and Glioblastoma.
• USA Expanded Access Program (EAP) FDA-authorized Expanded Access (Compassionate Use) Program that allows eligible U.S. patients with serious or life-threatening conditions — including dementia and Alzheimer's disease — to receive investigational TB006 outside of clinical trials when no satisfactory alternative treatments are available. Access is physician-mediated: licensed treating physicians apply on behalf of patients, complete training, and oversee monthly IV infusions in a clinical setting.
• Global Early Access Program Global program managed by TrueBinding to support patients with unmet medical needs across neurodegenerative diseases, oncology, systemic fibrosis, and metabolic syndromes, allowing physicians and patients outside the U.S. to access investigational TB006 prior to commercial approval. Operates through regional Named Patient Programs (e.g., Hong Kong Department of Health authorization) and physician-led early access pathways.

Quantifiable outcome

• 47% of patients showed cognitive improvement after 3 months of TB006 treatment in Open Label Extension study
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and regional.

• UCSF (University of California, San Francisco)coreStrategic or Co-development Partner · 1 November 2025TrueBinding partnered with UCSF to present new findings on TB006 for glioblastoma treatment in Neuro-Oncology journal (Nov 2025). Collaboration focuses on exploring TB006's potential to overcome immune evasion in GBM and enhance T-cell infiltration into tumors. UCSF's Dr. Mitchel Berger (Chair of Neurological Surgery) serves on TrueBinding's advisory board.
• Hong Kong Department of HealthregionalOthers · 1 April 2024Hong Kong Department of Health authorized a Named Patient Program (NPP) allowing access to investigational TB006 for eligible patients with dementia or Alzheimer's disease. TrueBinding is dedicated to assisting patients globally through Early Access Programs.
• Autism Discovery FoundationcoreStrategic or Co-development Partner · 1 January 2024Strategic partnership with leading ASD Foundation to investigate Gal-3 blockade in restoring homeostatic brain connectivity for autism spectrum disorder. The partnership supports the Phase 2a IIT clinical trial in adult ASD (NCT06500637) with investigators Dr. Richard Frye and Dr. Dan Rossignol.
• University of Kansas Medical CentercoreStrategic or Co-development Partner · 1 January 2022Dr. Rajesh Pahwa, Chief of Parkinson's and Movement Disorder Division and Director of Parkinson Foundation Center of Excellence at University of Kansas Medical Center, serves on TrueBinding's team. Supports Parkinson's disease clinical trial program.
• NYU Langone HealthcoreStrategic or Co-development Partner · 1 January 2022Dr. Thomas M. Wisniewski, Director of NYU Alzheimer's Disease Research Center and Center for Cognitive Neurology, serves on TrueBinding's team. Supports Alzheimer's disease research and clinical development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Biogen: Biogen co-developed Leqembi (lecanemab), the first FDA-approved anti-amyloid mAb for Alzheimer's disease. As the established leader in neurodegenerative mAb therapeutics, Biogen is the most direct commercial competitor for TB006 in the Alzheimer's space.
• Eli Lilly: Eli Lilly developed and received FDA approval for Kisunla (donanemab), another anti-amyloid mAb for Alzheimer's. As a major pharma with extensive Alzheimer's clinical and commercial infrastructure, Lilly represents both a competitor and potential strategic acquirer or partner for TrueBinding.
• Roche: Roche developed gantenerumab (which failed Phase 3) for Alzheimer's and has a broad neuroscience portfolio including other neurodegeneration programs. As a major pharma, Roche represents a potential strategic partner or acquirer for TrueBinding.
• AbbVie: AbbVie has a substantial neuroscience and immunology franchise and has historically pursued neurodegeneration through partnerships and acquisitions. As a major pharma with capital and commercial reach, AbbVie could be a potential strategic acquirer or partner for TrueBinding.

Direct peers

• Alector: Alector is a clinical-stage biotechnology company developing immuno-neurology therapeutics for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. Its mechanism of targeting microglial and innate immune dysfunction is conceptually similar to TrueBinding's Gal-3 targeting approach.
• Denali Therapeutics: Denali Therapeutics is a clinical-stage biotech developing therapeutics for neurodegeneration with a focus on biomarker-driven development and brain-penetrant molecules. It shares TrueBinding's profile as a multi-program, neuroscience-focused biotech.
• Prothena: Prothena is developing monoclonal antibody therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's. Its pipeline of protein-misfolding targeted mAbs competes in the same therapeutic indications as TB006.
• Acumen Pharmaceuticals: Acumen Pharmaceuticals is a clinical-stage biotech developing monoclonal antibody therapeutics targeting amyloid-beta oligomers for early Alzheimer's disease. It is a direct mechanism-comparable peer to TB006.

Emerging players

• Cassava Sciences: Cassava Sciences is developing simufilam, a small molecule for Alzheimer's disease, with controversial Phase 2/3 data. It competes in the same indication as TB006 but with a different modality and scientific approach.
• Cognition Therapeutics: Cognition Therapeutics is a clinical-stage company developing CT1812, a small molecule sigma-2 receptor modulator for Alzheimer's disease. It targets a similar patient population to TB006 but with a differentiated mechanism.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/truebindingco

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TrueBinding